The agreement gives Shire exclusive worldwide rights to develop tissue protective cytokines (TPCs) in non-nervous system indications, including renal and genetic disease areas. TPCs are modifications of erythropoietin
Under terms of the agreement, UCB will receive upfront and additional payments for development and commercial milestones in excess of $200 million dollars. Furthermore, Biogen Idec will contribute
Adecatumumab (MT201) is being developed in collaboration between Micromet and Serono. The product candidate was assessed as a single agent for efficacy and safety in patients. Serono commented
The talks to acquire Vision Systems (VSL) come after rival bidder Cytyc proposed an offer of $692 million. It has raised its bid to $3.25 a share, up
Xelox has been developed as a treatment for colorectal cancer and includes the oral Xeloda and an infusion of the chemotherapy drug oxaliplatin. The data also showed that
Under terms of the agreement, Takeda is responsible for all development and commercialization activities in the licensed territories. Xenon will receive an upfront cash payment of up to
Peramivir also improved survival rates in animal subjects who were infected with the H5N1 strain of the virus – a potentially vital discovery in the attempt to find
The transaction has been structured as a two-step acquisition comprised of a cash tender offer for all of the outstanding Myogen common stock at $52.50 per share, followed
The phase I trial of AS1411 initially recruited patients with various cancers. During 2005, it was extended to recruit additional patients with renal and lung cancers. The findings
In the phase III clinical trial, the median time to progression increased significantly from 13.8 to 18.2 months. HER2-positive breast cancer, which affects approximately 20% to 30% of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.